Leading UK Timber Processor and Packaging Manufacturer, James Jones & Sons Ltd., Adopts Intelligent Bio Solutions’ Fingerprint Drug Screening System Across its 25 Sites and 1,300 Employees
29 Gennaio 2024 - 2:30PM
Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or the
“Company”), a medical technology company delivering intelligent,
rapid, non-invasive testing solutions, today announced that leading
UK timber processor and packaging manufacturer, James Jones &
Sons Ltd is now using its revolutionary portable Intelligent
Fingerprinting Drug Screening System that works by analyzing
fingerprint sweat.
James Jones & Sons Ltd will use 11 readers
deployed across the company’s 25 UK locations. The company will
implement a random testing program for its 1,300 employees to
proactively support its new substance misuse policy launched in
November 2023.
Rosetta Forbes, Group Head of HR for James Jones
& Sons Ltd, said, “James Jones has some 1,300 employees, many
of whom operate high-risk machinery such as sawmill cutting
equipment, pallet & packaging manufacturing units, and wood
harvesting machinery. As an innovative company, we want to push our
safety record forward, and Intelligent Fingerprinting will be
central to our new substance misuse policy.”
“We are rolling out the Intelligent
Fingerprinting Drug Screening System to provide in-house testing
that will be available across all our sites, including our
remote/rural operations, as required,” added Rosetta Forbes. “The
system is a great match for our needs. It is easy for our HR and
Health and Safety colleagues who are not medically trained to use.
The system is non-invasive, fast, and cost-effective across our
urban as well as remote locations, with easy sample collection that
takes only seconds. On-site results for multiple drug groups in
just ten minutes makes Intelligent Fingerprinting a very efficient
and innovative solution for James Jones & Sons Ltd to
adopt.”
James Jones & Sons Ltd’s in-house HR team
will work collaboratively with their Health and Safety colleagues,
as well as some local managers, who are all trained to use the
sweat-based drug screening system to manage testing as required.
The company has carefully planned the roll-out, incorporating a
company-wide amnesty period that welcomes employees to approach the
company for wellbeing support before the new policy came into force
in December.
Harry Simeonidis, President and Chief Executive
Officer of Intelligent Bio Solutions Inc., said, “For workplace
testing, the Intelligent Fingerprinting Drug Screening System
offers companies full control and the ability to drug test quickly,
conveniently, and whenever needed. This enables organizations such
as James Jones & Sons Ltd to be proactively responsible for the
health and safety of its employees and customers while protecting
its business reputation.”
James Jones has purchased 11 Intelligent
Fingerprinting Drug Screening Systems consisting of portable
DSR-Plus readers and single-use chain of custody sample collection
cartridges. These will be located at the company's testing hubs
that will geographically cover their 25 locations across the UK.
The company’s Australian operations are also watching the
deployment with a view to potentially expand the use of the system
to that region.
An introductory video demonstrating
fingerprint-based drug testing in action is available here.
About Intelligent Bio Solutions
Inc.
Intelligent Bio Solutions Inc. (NASDAQ: INBS) is
a medical technology company delivering innovative, rapid,
non-invasive testing solutions. The Company believes that its
Intelligent Fingerprinting Drug Screening System will revolutionize
portable testing through fingerprint sweat analysis, which has the
potential for broader applications in additional fields. Designed
as a hygienic and cost-effective system, the test screens for
recent use of drugs commonly found in the workplace, including
opiates, cocaine, methamphetamine, and cannabis. With sample
collection in seconds and results in under ten minutes, this
technology would be a valuable tool for employers in
safety-critical industries. Additionally, the Company's biosensor
platform has the potential to test for up to 130 indications,
ranging from glucose to immunological conditions and communicable
diseases. The Company's current customer segments include
construction, manufacturing and engineering, transport and
logistics firms, drug treatment organizations, and coroners.
For more information, visit:
http://www.ibs.inc/
About James Jones
James Jones & Sons Ltd is a 5th generation
family business and one of the UK’s largest and most progressive
timber processing companies with core activities in timber
harvesting, sawmilling, pallets & packaging, and distribution.
We operate from 25 sites across the UK, 11 Australian and 2 New
Zealand sites, and employ over 2,100 people. In the UK, we operate
seven sawmills throughout Scotland and the northeast of England: an
engineered wood manufacturing plant in the north of Scotland and
pallet and packaging operations at 14 sites across the UK. We
produce high quality, British grown timber for the UK construction,
landscaping, and agricultural sectors; market-leading JJI-Joists
for the housebuilding and construction markets and pallets and
packaging for blue chip domestic and exporting businesses. For
further information on James Jones & Sons Ltd, visit:
https://www.jamesjones.co.uk
Forward-Looking Statements:
Some of the statements in this release are
forward-looking statements within the meaning of Section 27A of the
Securities Act of 1933, Section 21E of the Securities Exchange Act
of 1934 and the Private Securities Litigation Reform Act of 1995,
which involve risks and uncertainties. Forward-looking statements
in this press release include, without limitation, Intelligent Bio
Solutions Inc.’s ability to develop and commercialize its
diagnostic tests, realize commercial benefit from its partnerships
and collaborations, and secure regulatory approvals, among others.
Although Intelligent Bio Solutions Inc. believes that the
expectations reflected in such forward-looking statements are
reasonable as of the date made, expectations may prove to have been
materially different from the results expressed or implied by such
forward-looking statements. Intelligent Bio Solutions
Inc. has attempted to identify forward-looking statements by
terminology, including “believes,” “estimates,” “anticipates,”
“expects,” “plans,” “projects,” “intends,” “potential,” “may,”
“could,” “might,” “will,” “should,” “approximately” or other words
that convey uncertainty of future events or outcomes to identify
these forward-looking statements. These statements are only
predictions and involve known and unknown risks, uncertainties, and
other factors, included in Intelligent Bio Solutions’ public
filings filed with the Securities and Exchange Commission. Any
forward-looking statements contained in this release speak only as
of its date. Intelligent Bio Solutions undertakes no obligation to
update any forward-looking statements contained in this release to
reflect events or circumstances occurring after its date or to
reflect the occurrence of unanticipated events.
Company Contact:Intelligent Bio
Solutions Inc.info@ibs.incLinkedIn | TwitterMedia
Contact:Cheryl BillsonComma
Communicationscheryl.billson@commacomms.com+44 (0)7791 720460
Grafico Azioni Intelligent Bio Solutions (NASDAQ:INBS)
Storico
Da Mag 2024 a Giu 2024
Grafico Azioni Intelligent Bio Solutions (NASDAQ:INBS)
Storico
Da Giu 2023 a Giu 2024